Treatment with Antithrombotics in the Last Year of Life—Incidence of Bleeding and Side Effects After Deprescribing
Journal of Palliative Medicine · 2024
DOI: 10.1089/jpm.2024.0108 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Palliative Medicine, 2024. Verfasst von Gabriella Frisk und 3 weiteren Autor:innen. Beteiligte Einrichtung: ASIH Stockholm Södra, Specialized home care and Specialized palliative ward, Älvsjö, Sweden. Hauptthemen laut MEDLINE: Deprescriptions, Fibrinolytic Agents, Hemorrhage. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 35 Literaturangaben.
Abstract (Originalsprache)
Background
Patients in palliative care are often treated with antithrombotics, even in the late stages of disease. Clear guidelines regarding deprescribing are lacking.
Objective
The aims of this study were to investigate bleeding as a side effect of antithrombotic treatments the last year in life and map the timing of deprescribing.
Methods
A retrospective cohort study was performed. All medical records were screened for deceased patients admitted to a palliative care unit in Stockholm, Sweden, over a 3-year period. Patients with antithrombotics were identified; data on bleeding, and on side effects due to deprescribing, were extracted from the medical records. Log-binomial models were used to explore factors associated with bleeding.
Results
Of 1501 patients, 897 were treated with antithrombotics during the last year of life (mean age 75 years, 41% women). Of these, 56% continued treatment up until the last 3 days of life. Of the 897 patients, 144 (16%) had at least one bleeding during the treatment. The risk for bleeding was significantly higher for men with prostate cancer compared to other cancer forms, adjusted relative risk 1.9 (95% CI 1.1–3.2). No difference in risk for bleeding was found between sex, age groups, type of antithrombotics, or indication. Two patients (0.2%) developed strokes after antithrombotics were deprescribed.
Conclusions
Treatment with antithrombotics during the last year of life is associated with a high risk of bleeding. In this cohort, men with prostate cancer seemed to have more side effects of bleeding than other groups. Few experienced side effects from deprescribing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- ASIH Stockholm Södra, Specialized home care and Specialized palliative ward, Älvsjö, Sweden.
- Department of Neurobiology, Care Sciences and Society (NVS), Division of Clinical Geriatrics, Karolinska Institutet, Huddinge, Sweden.
- Department of Medical Epidemiology and Biostatistics, C8 Medicinsk epidemiologi och biostatistik, MEB Jonell, Karolinska Institutet, Stockholm, Sweden.
- Stockholms Sjukhems R&D Department, Stockholm, Sweden.
- Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinician Sciences Lund, Lund University, Lund, Sweden.
ORCID-Profile: Gabriella Frisk, Linda Björkhem-Bergman
Zitieren
APA
Frisk, G., Szilcz, M., Hedman, C., & Björkhem-Bergman, L. (2024). Treatment with Antithrombotics in the Last Year of Life—Incidence of Bleeding and Side Effects After Deprescribing. Journal of Palliative Medicine. https://doi.org/10.1089/jpm.2024.0108
Vancouver
Frisk G, Szilcz M, Hedman C, Björkhem-Bergman L. Treatment with Antithrombotics in the Last Year of Life—Incidence of Bleeding and Side Effects After Deprescribing. Journal of Palliative Medicine. 2024. doi:10.1089/jpm.2024.0108
BibTeX
@article{Frisk2024,
author = {Frisk, Gabriella and Szilcz, Máté and Hedman, Christel and Björkhem-Bergman, Linda},
title = {Treatment with Antithrombotics in the Last Year of Life—Incidence of Bleeding and Side Effects After Deprescribing},
journal = {Journal of Palliative Medicine},
year = {2024},
doi = {10.1089/jpm.2024.0108}
}
EUVIMED